Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still

Group 1 - Exelixis (EXEL) has been a subject of interest for years, with fluctuating investment sentiment between "Do Not Buy" and "Regret Not Buying" [1] - The author has a PhD in biochemistry and extensive experience in analyzing clinical trials and biotech companies, emphasizing the importance of understanding the science behind investments [1] Group 2 - The article does not provide any specific financial data or performance metrics related to Exelixis or the biotech industry [2][3]